[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371358-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371358-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","anxiety-and-depression-in-patients-with-histiocytic-neoplasms-and-their-associated-clinical-features","Anxiety and Depression in Patients with Histiocytic Neoplasms and Their Associated Clinical Features","","Anxiety and depression are common across many cancers, but their prevalence and associated clinical factors in histiocytic neoplasms (HNs) have not been systematically studied. A registry-based cohort of HN patients completing patient-reported outcomes from 2018 to 2023 was analyzed using the Hospital Anxiety and Depression Scale (HADS), with moderate to severe anxiety or depression defined by HADS scores ≥11. In 215 patients, about one-third met criteria for anxiety or depression and one in seven met moderate or severe criteria, remaining stable over a 12-month trajectory.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/anxiety-and-depression-in-patients-with-histiocytic-neoplasms-and-their-associated-clinical-features/371358/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/anxiety-and-depression-in-patients-with-histiocytic-neoplasms-and-their-associated-clinical-features/371358.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What proportion of patients with histiocytic neoplasms reported anxiety or depression?","Question",{"text":63,"@type":64},"About 1 in 3 patients met criteria for anxiety or depression. About 1 in 7 met criteria for moderate or severe anxiety or depression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were anxiety and depression measured in the study?",{"text":68,"@type":64},"Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS). Moderate or severe symptoms were defined as HADS scores ≥11 on the relevant subscales.",{"name":70,"@type":61,"acceptedAnswer":71},"Were anxiety and depression stable over time?",{"text":72,"@type":64},"Yes. Rates remained stable over a 12-month trajectory.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371358,1790224032,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","REGULAR ARTICLE  \nAnxiety and depression in patients with histiocytic neoplasms and their associated clinical features  \nAnne S. Reiner, 1 Yesne Alici,2 Denise D. Correa,3 Dana Bossert,3 Allison M. Sigler,3 Deanna Fournier,4 Kathleen Brewer,5 Gaurav Goyal,6 Thomas M. Atkinson,2 Priya Marathe,7 Jun J. Mao,8 Katherine S. Panageas, 1 and Eli L. Diamond3, 9  \n1 Department of Epidemiology and Biostatistics, 2 Department of Psychiatry and Behavioral Sciences, and 3 Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY; 4 Histiocytosis Association, Pitman, NJ; 5 Erdheim-Chester Disease Global Alliance, DeRidder, LA; 6 Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL; 7 Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY; and 8 Integrative Medicine Service, Department of Medicine and 9 Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY  \nKey Points  \n• One in 3 patients with HNs report anxiety or depression, and 1 in 7 report moderate or severe anxiety or depression.  \n• Anxiety and depression are stable over time and correlated with ﬁnancial burden, symptom severity, and HRQoL.  \nAnxiety and depression are common in many cancers but, to our knowledge, have not been systematically studied in patients with histiocytic neoplasms (HNs) . We sought to estimate rates of anxiety and depression and identify clinical features and patient-reported outcomes (PROs) associated with anxiety and depression in patients with HNs. A registrybased cohort of patients with HNs completing PROs including the hospital anxiety and depression scale (HADS) from 2018 to 2023 was identiﬁed. Moderate or severe anxiety or depression were respectively deﬁned as a score of ≥11 on the HADS anxiety or depression subscales. Associations of variables, including other validated PROs, with moderate or severe anxiety or depression were modeled with logistic regression to estimate odds ratiosand 95% conﬁdence intervals. In 215 patients, ~1 in 3 met the criteria for anxiety or depression, and 1 in 7 met the criteria for moderate or severe anxiety or depression. These estimates remained stable over a 12-month trajectory. Rates of depression, but not anxiety, signiﬁcantly differed across HN types, with patients with Erdheim-Chester disease experiencing the highest rate. In addition, neurologic involvement, unemployment, and longer undiagnosed illness interval were signiﬁcantly associated with increased risk of depression. Financial burden, ﬁnancial worry, and severe disease-related symptoms were correlated with increased risk of both anxiety and depression. Conversely, increased general and cognitive health-related quality of life (HRQoL) were correlated with decreased risk of both anxiety and depression. In patients with HN, anxiety and depression are prevalent, stable over time, and correlated with ﬁnancial burden, symptom severity, and HRQoL. This trial was registered at [www.clinicaltrials.gov](www.clinicaltrials.gov) as \\#NCT03329274 .  \nIntroduction  \nAnxiety is a multifaceted emotional state characterized by feelings of worry and can include physical and autonomic changes in reaction or anticipatory reaction to threats or stressors.1 Depression is a psychological state characterized by feelings of sadness and hopelessness, often accompanied by cognitive and physical symptoms. Across all cancer types, ~1 in 10 patients report depression and 1 in  \nSubmitted 19 September 2024; accepted 18 October 2024; prepublished online on Blood Advances First Edition 3 December 2024. [https://doi.org/10.1182/](https://doi.org/10.1182/)[ ](https://doi.org/10.1182/)[bloodadvances.2024014850](bloodadvances.2024014850.)[.](bloodadvances.2024014850.)  \nOriginal data are available on request from the corresponding author, Eli L. Diamond ([diamone1@mskcc.org](diamone1@mskcc.org)).  \nThe full-text version of this article contains a data supplement.  \n","cbCaidC619Ha0FbC","https://ap.wps.com/l/cbCaidC619Ha0FbC","pdf",997517,11,"English","# Key Points\n# Introduction\n# Methods\n## Study approach and measures","[{\"question\":\"What proportion of patients with histiocytic neoplasms reported anxiety or depression?\",\"answer\":\"About 1 in 3 patients met criteria for anxiety or depression. About 1 in 7 met criteria for moderate or severe anxiety or depression.\"},{\"question\":\"How were anxiety and depression measured in the study?\",\"answer\":\"Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale (HADS). Moderate or severe symptoms were defined as HADS scores ≥11 on the relevant subscales.\"},{\"question\":\"Were anxiety and depression stable over time?\",\"answer\":\"Yes. Rates remained stable over a 12-month trajectory.\"}]","Anxiety and Depression in Patients with Histiocytic Neoplasms and Their Associated Clinical Features | PDF",1790191890,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c46b229ce33b21fa0b6f5981ab0f1384.webp",983,1296,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2b73ff8aa4320690659ffa2fe27fa40.webp",982,1294,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c4596807b52a734d83e1524032244a1.webp",981,743,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22ef55c56e4249d1163ebad61da81d45.webp",980,1292]